SuperGen Reports 2008 Second Quarter Financi...(proliferation in vivo (abstract #741). ...)

titled "SGI-1252: A Potent Small Molecule JAK2 Inhibitor," Dr.

Steven Warner, Manager of Discovery Biology, highlighted how

SuperGen scientists used the Company's CLIMB technology to identify

SGI-1252 as a possible JAK2 inhibitor. Dr. Warner presented data

indicating that SGI-1252 selectively inhibits wildtype and mutant

JAK2 activity in cancer cell lines, resulting in inhibition of STAT5

phosphorylation as well as a reduction in Bcl-XL expression.

SGI-1252 was also shown to inhibit tumor growth in mouse xenograft

models. Pharmacokinetic studies suggest that SGI-1252 is orally

bioavailable.

-- July 2008: The Company commented on the preliminary data from a Phase

3 trial, initiated in 2002, comparing Dacogen to best supportive care

(BSC) in elderly patients with myelodysplastic syndromes (MDS). The

data did not demonstrate a statistically significant advantage of

Dacogen treatment on median survival compared to BSC, the primary

endpoint of the study. However, response rates were similar to those

observed in other clinical trials of Dacogen in patients with MDS. The

trial, conducted by the European Organisation for Research and

Treatment of Cancer (EORTC), administered Dacogen on a three-day dosing

schedule in which the number of treatment cycles was limited. MDS is a

potentially life-threatening group of bone marrow diseases that limit

the production of functional blood cells. Subsequent to database lock

and the completion of data analysis, comprehensive results of the

study, including secondary efficacy endpoints and safety data, will be

presented by EORTC at an upcoming scientific forum.

Conference Call Information

SuperGen will ho
'/>"/>